Last reviewed · How we verify
NCT07457541
Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI
Phase 1 trial testing [99mTc]Tc-HYNIC-FAPI in Lung Cancer (Locally Advanced or Metastatic) in 15 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2026
Quick facts
| Lead sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences |
|---|---|
| Phase | Phase 1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 15 |
| Start date | 26 February 2026 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 May 2027 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- [99mTc]Tc-HYNIC-FAPI — full drug profile →
Conditions studied
- Lung Cancer (Locally Advanced or Metastatic) — all drugs for Lung Cancer (Locally Advanced or Metastatic) →
- Pancreas Cancer, Metastatic — all drugs for Pancreas Cancer, Metastatic →
- Breast Cancer (Locally Advanced or Metastatic) — all drugs for Breast Cancer (Locally Advanced or Metastatic) →
- Colorectal Cancer (Locally Advanced or Metastatic) — all drugs for Colorectal Cancer (Locally Advanced or Metastatic) →
Sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Who can join
Adults 18 to 75, any sex, with Lung Cancer (Locally Advanced or Metastatic) or Pancreas Cancer, Metastatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study should evaluate the biological distribution of 99mTc-HYNIC-FAPI in metastatic cancer patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07457541
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Tomsk National Research Medical Center of the Russian Academy of Sciences trials
Trials by the same sponsor.
- NCT07475390 — 99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging · NA · active not recruiting
- NCT07292571 — Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 · Phase 2 · enrolling by invitation
- NCT07275463 — [99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression · Phase 2 · enrolling by invitation
- NCT07018895 — Personalized Hypoxic-hyperoxic Preconditioning in Elderly People · NA · completed
- NCT06759259 — Mannitol Administration for Delerium Prevention · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07457541 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tomsk National Research Medical Center of the Russian Academy of Sciences
- Last refreshed: 12 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07457541.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing